Surprisingly anti-CCL2 monoclonal antibody treatment did not affect TAM recruitment but polarized TAMs to a more antitumor phenotype, where the tumor regression was CD8+ T-cell dependent in a murine NSCLC cancer model [123] (Table 1). This evidence concerns the gene CCL2 and cancer.